头颈癌免疫检查点抑制剂停药后化疗的疗效
该回顾性研究纳入2017年以来在本机构接受ICI治疗的99例连续病例中的79例已停用ICI的头颈部鳞状细胞癌患者,比较停药后积极治疗(40例,其中挽救性化疗33例、手术或放疗7例)与非积极治疗(39例)的疗效;结果显示积极治疗较非积极治疗显著提高总生存期,PTX-Cmab方案与总缓解率显著相关,但各挽救性化疗方案间总生存期或无进展生存期无显著差异。
要点
- ICI停药后积极治疗较非积极治疗显著提高总生存期。
- 各挽救性化疗方案间总生存期或无进展生存期无显著差异,PTX-Cmab有生存获益趋势。
- 多因素分析显示总缓解率与PTX-Cmab治疗显著相关。
核心结论
- ICI停药后积极治疗以及使用PTX-Cmab作为挽救性化疗可能提高头颈部鳞状细胞癌的总生存期。
研究设计与样本
- 回顾性研究,来自本机构2017年以来接受ICI治疗的99例连续病例的住院病历,其中79例已停用ICI的鳞状细胞癌病例纳入本研究。
主要发现
- ICI停药后,40例接受积极治疗(挽救性化疗33例,手术或放疗7例),39例接受非积极治疗。
- 积极治疗较非积极治疗观察到总生存期显著增加。
- 各挽救性化疗方案间总生存期或无进展生存期无显著差异,但PTX-Cmab有生存获益趋势。
- 总缓解率单因素分析显示,ICI时的疾病部位和挽救性化疗方案存在显著差异。
- 各挽救性化疗方案间疾病控制率存在显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint inhibitors (ICI) have become widely used becuse of their effectiveness and relatively low rate of severe adverse events. However, active treatment should be continued after discontinuation of ICI as response rates are lower than that of conventional cytotoxic chemotherapy. The purpose of the present study was to determine the efficacy of treatment after ICI discontinuation. METHODS: This was a retrospective study from hospital charts of 99 consecutive cases treated with ICI at our facility since 2017. Of these, 79 cases of squamous cell carcinoma which had already discontinued ICI were enrolled in the present study. RESULTS: After discontinuation of ICI, 40 cases received active treatment with salvage chemotherapy (SCTx; 33 cases) or surgery or radiotherapy (seven patients) and 39 cases received nonactive treatment. SCTx comprising paclitaxel and cetuximab (PTX-Cmab) was administered to 15 cases and other SCTx regimens to 18 cases. A significant increase in overall survival (OS) was observed with active treatment compared with nonactive treatment. No significant differences in OS or progression-free survival (PFS) were observed between SCTx regimens; however, there was a trend toward increased survival with PTX-Cmab. Univariate analysis of overall response rate (ORR) demonstrated significant differences in the site of disease at ICI and SCTx regimens. A significant difference in disease control rate was observed between SCTx regimens. Multivariate analysis of ORR demonstrated a significant correlation with PTX-Cmab treatment. CONCLUSION: Active treatment after ICI discontinuation and the use of PTX-Cmab as SCTx may increase OS in head and neck squamous cell carcinoma. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:228-235, 2024.
引用
- Fukuoka O, Saito Y, Mukai T, et al. Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer. Laryngoscope. 2023. PMID: 37377185. doi:10.1002/lary.30851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。